for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Yumanity Therapeutics Inc

YMTX.OQ

Latest Trade

3.75USD

Change

-0.08(-2.09%)

Volume

58,147

Today's Range

3.63

 - 

3.87

52 Week Range

3.63

 - 

26.20

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.83
Open
3.80
Volume
58,147
3M AVG Volume
4.64
Today's High
3.87
Today's Low
3.63
52 Week High
26.20
52 Week Low
3.63
Shares Out (MIL)
10.31
Market Cap (MIL)
39.48
Forward P/E
-1.08
Dividend (Yield %)
--

Next Event

Q4 2021 Yumanity Therapeutics Inc Earnings Release

Latest Developments

More

Yumanity Therapeutics Reports Q3 Loss Per Share $0.97

Yumanity Therapeutics Announces Positive Top-Line Results Of Phase 1B Clinical Trial For Ytx-7739 In Patients With Parkinson’S Disease Company Plans To Advance Program To Phase 2

Yumanity Therapeutics Posts Q2 Loss Per Share Of $1.03

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Yumanity Therapeutics Inc

Yumanity Therapeutics Inc., formerly Proteostasis Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. The Company's technology platform enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks. The Company's product candidate, YTX-7739, is in Phase I clinical trials for the treatment and disease modification of Parkinson's disease and YTX-9184, in IND-enabling studies for the treatment of dementia with Lewy bodies. The Company's pipeline consists of additional programs for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's Disease) and frontotemporal lobar degeneration (FTLD) is undergoing research through Merck.

Industry

Biotechnology & Drugs

Contact Info

40 GUEST STREET, SUITE 4410

BOSTON, MA

02135

United States

+1.617.4095300

https://www.yumanity.com/

Executive Leadership

N. Anthony Coles

Non-Executive Chairman of the Board

Richard Peters

President, Chief Executive Officer, Director

Michael D. Wyzga

Chief Financial Officer, Senior Vice President

Ajay Verma

Executive Vice President, Head of Research & Development

Paulash Mohsen

Chief Business Officer

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-32.200

2019

-23.200

2020

-8.520

2021(E)

-3.900
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.78
Price To Book (MRQ)
1.22
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
44.64
LT Debt To Equity (MRQ)
26.95
Return on Investment (TTM)
-119.09
Return on Equity (TTM)
-96.06

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up